Also known as Votrient
Pazopanib (trade name Votrient) is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that blocks tumor growth and inhibits angiogenesis. It has been approved for renal cell carcinoma and soft tissue sarcoma by the U.S. Food and Drug Administration. Pazopanib may also be active in ovarian cancer Pazopanib also appears effective in the treatment of non-small cell lung carcinoma.Source: Wikipedia
Estimated Total Cost: $4822.95 for an average of 28 days supply
Patients are most commonly prescribed pazopanib to treat rabies, blastomycosis, west nile virus, and pick disease.